RCT: BBV152 (India’s COVAXIN) has an overall vaccine efficacy of 77.8% against symptomatic Covid-19 in adults.

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial – The Lancet

Invited Commentary: Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19 – The Lancet

Related: WHO issues emergency use approval for India’s Covaxin.

Commentary on Twitter

NEW—Interim data from a phase 3 trial of #BBV152, a COVID-19 vaccine developed in India, suggests it is safe and two doses offer 77.8% protection against symptomatic #COVID19. https://t.co/QWtz0AWd1X

— The Lancet (@TheLancet) November 11, 2021